[ABSTRAK Demam berdarah dengue (DBD) merupakan penyakit yang disebabkan karenainfeksi virus dengue (DENV), yang banyak ditemukan di Indonesia. Belum adaterapi yang spesifik dalam pengobatan DBD. Upaya pengembangan vaksindengue yang efektif sangat diperlukan. Pada penelitian ini dilakukan analisaimunogenisitas kandidat vaksin DNA prM-E dengue serotipe 2 (pUMD2.kl.20)dengan menganalisis sel T CD4, sel T CD8, IFN-γ dan TNF-α. pada sel U937 danPBMC secara in vitro, bertujuan untuk mengetahui respon imun ketika vaksindiinjeksikan ke dalam tubuh manusia. Dasar penelitian ini adalah sel U937ditransfeksi dengan pUMD2.kl.20 menggunakan lipofectamin. Sel U937 akanberperan sebagai APCs yang akan mengekspresikan protein prM-E DENV-2 danmempresentasikan protein tersebut melalui molekul MHC class I dan MHC classII kepada Peripheral Blood Mononuclear Cell (PBMC) manusia. Tahapan kerjayang dilakukan dalam penelitian ini terdiri dari: (a) kultur galur sel U937, (b)transfeksi sel U937 dengan pUMD2.kl.20, (c) transfeksi sel U937 dengan plasmids(pUMVC), (d) infeksi sel U937 dengan DENV-2 strain DS.18/09, (e) pewarnaandan pengamatan hasil pewarnaan menggunakan alat semi flowcytometri (TALI).pUMD2.kl.20 mengaktivasi sel T CD4 dan sel T CD8 untuk berploriferasi. Hasilpenelitian ini menunjukkan bahwa konsentrasi sel T CD8 lebih tinggi darikonsentrasi sel T CD4 dan konsentrasi sel positif yang mensekresikan IFNγ lebihtinggi dari konsentrasi sel positif yang mensekresikan TNFα. Kondisi optimal dariaktivasi sel T CD4 oleh pUMD2.kl.20 adalah 24 jam setelah penambahan PBMCsetelah transfeksi (8,53x10⁴sel/ml), untuk sel T CD8 adalah 24 jam setelahpenambahan PBMC setelah transfeksi (49,4x10⁴ sel/ml). Kondisi optimal dariaktivasi sel+ yang mensekresikan IFNγ oleh pUMD2.kl.20 adalah 24 jam setelahpenambahan PBMC 48 jam setelah transfeksi (9,86x10⁴ sel/ml), dan untuk sel+yang mensekresikan TNFα adalah 2 jam setelah penambahan PBMC 48 jamsetelah transfeksi (2,1x10⁴ sel/ml). Dari penelitian ini dapat disimpulkan bahwapUMD2.kl.20 bersifat imunogenik. ABSTRACT Dengue hemorrhagic fever (DHF) is a disease caused by infection with denguevirus (DENV), which is found in Indonesia. There is no specific therapy in thetreatment of DHF. An effort to develop an effective dengue vaccine is needed. Inthis research, analysis of the immunogenicity of the DNA vaccine candidate prMEdengue serotype 2 (pUMD2.kl.20) by analyzing the CD4 T cells, CD8 T cells,IFN-γ and TNF-α in U937 cells and PBMC in vitro, aims to determine theimmune response when the vaccine is injected into the human body. This researchapproach is based on transfection of U937 cells with pUMD2.kl.20 usinglipofectamin. U937 cells acts as APCs which will express the protein prM-EDENV-2 and presenting these proteins through the MHC class I and MHC class IImolecule to the Peripheral Blood Mononuclear Cell (PBMC) of human body.Stages of the work in this study consisted of: (a) culture cell line U937, (b)transfection of U937 cells with pUMD2.kl.20, (c) transfection of U937 cells withplasmid (pUMVC), (d) infection of U937 cells with DENV-2 strains DS.18/09,(e) staining and observation results of staining using a semi-flow cytometri(TALI). pUMD2.kl.20 activate CD4 T cells and CD8 T cells to proliferate. CD8 Tcells concentration higher than the concentration of CD4 T cells and the secretionof INFγ-positive cells concentration higher than the concentration of the secretionof TNFα-positive cells. Optimal condition of CD4 T cells activation bypUMD2.kl.20 is 24 hours after the addition of PBMC after transfection (8,53x10⁴cells/ml), for CD8 T cells was 24 hours after the addition of PBMC aftertransfection (49,4x10⁴ cells/ml). Optimal conditions secretion of IFNγ-positivecells were activated by pUMD2.kl.20 is 24 hours after the addition of PBMC 48hours after transfection (9,86x10⁴ cells/ml), and for the secretion of TNFα-positive cells were activated by pUMD2.kl.20 is 2 hours after the addition ofPBMC 48 hours after transfection (2,1x10⁴ cells/ml). From this study it can beconcluded that the pUMD2.kl.20 immunogenic, Dengue hemorrhagic fever (DHF) is a disease caused by infection with denguevirus (DENV), which is found in Indonesia. There is no specific therapy in thetreatment of DHF. An effort to develop an effective dengue vaccine is needed. Inthis research, analysis of the immunogenicity of the DNA vaccine candidate prMEdengue serotype 2 (pUMD2.kl.20) by analyzing the CD4 T cells, CD8 T cells,IFN-γ and TNF-α in U937 cells and PBMC in vitro, aims to determine theimmune response when the vaccine is injected into the human body. This researchapproach is based on transfection of U937 cells with pUMD2.kl.20 usinglipofectamin. U937 cells acts as APCs which will express the protein prM-EDENV-2 and presenting these proteins through the MHC class I and MHC class IImolecule to the Peripheral Blood Mononuclear Cell (PBMC) of human body.Stages of the work in this study consisted of: (a) culture cell line U937, (b)transfection of U937 cells with pUMD2.kl.20, (c) transfection of U937 cells withplasmid (pUMVC), (d) infection of U937 cells with DENV-2 strains DS.18/09,(e) staining and observation results of staining using a semi-flow cytometri(TALI). pUMD2.kl.20 activate CD4 T cells and CD8 T cells to proliferate. CD8 Tcells concentration higher than the concentration of CD4 T cells and the secretionof INFγ-positive cells concentration higher than the concentration of the secretionof TNFα-positive cells. Optimal condition of CD4 T cells activation bypUMD2.kl.20 is 24 hours after the addition of PBMC after transfection (8,53x10⁴cells/ml), for CD8 T cells was 24 hours after the addition of PBMC aftertransfection (49,4x10⁴ cells/ml). Optimal conditions secretion of IFNγ-positivecells were activated by pUMD2.kl.20 is 24 hours after the addition of PBMC 48hours after transfection (9,86x10⁴ cells/ml), and for the secretion of TNFα-positive cells were activated by pUMD2.kl.20 is 2 hours after the addition ofPBMC 48 hours after transfection (2,1x10⁴ cells/ml). From this study it can beconcluded that the pUMD2.kl.20 immunogenic] |